
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. is positioned favorably due to the strong momentum of its lead product, Auvelity, in managing major depressive disorder (MDD), supported by its novel mechanism of action and rapid onset of efficacy. Recent progress with AXS-05, including received FDA meeting minutes that outline a path for sNDA submission aimed at agitation in Alzheimer's disease, enhances confidence in its potential approval based on robust clinical trial outcomes demonstrating significant improvements in agitation symptoms. Additionally, the upcoming SYMBRAVO launch, which has shown rapid efficacy in migraine relief and enhanced quality of life metrics through controlled trials, is set to bolster Axsome's market presence and drive future growth.
Bears say
Axsome Therapeutics faces significant risks that negatively impact its outlook, including potential lower-than-expected market access for its product AUVELITY and setbacks in clinical trials, particularly for AXS-05 intended for treatment-resistant depression and smoking cessation. Additionally, the company's ability to secure timely approvals for its pipeline candidates AXS-12 and AXS-14 is uncertain, which could hinder its overall commercial success amidst anticipated competition. The presence of adverse events and the possibility of long-term dilution risk further compound the concerns regarding its financial stability and market performance.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares